UNASSIGNED: 294 Background: Combination chemotherapy is the standard of care for neoadjuvant, adjuvant, and metastatic @entity150 due to increased efficacy when compared to monotherapy. We report our experience with sequential intravesical combination chemotherapy using @entity136 and @entity1138 ( @entity1139 ) for non-muscle invasive @entity150 (NMIBC). METHODS: We performed a multi-institutional retrospective review of 47 consecutive @entity1 who received 6 weekly treatments with sequential @entity136 (1g) and @entity1138 (40mg) chemotherapy for NMIBC. Thirty @entity1 received treatment at University of Iowa, 14 at UCSF and 3 at University of Minnesota. RESULTS: A total 47 @entity1 (median age 70, range 32-85; 36 males, 11 females) previously failing a median of 2 intravesical treatments were reviewed. The complete response (CR), 1-year recurrence-free survival (1-RFS) and 2-year recurrence-free survival (2-RFS) for all @entity1 was 68%, 48% and 38%, respectively. In all, 14 of 47 @entity1 (30%) remain free of recurrence with a median time to followup of 26 months (range 6-80 months). The median time to recurrence for all @entity1 who recurred was 4 months (range 1-33 months). Ten @entity1 required cystectomy. CONCLUSIONS: Sequential intravesical combination chemotherapy using @entity136 and @entity1139 appears to be a useful treatment for @entity1 with a history of NMIC which has failed BCG or other intravesical therapy, in addition to @entity1 with intermediate and high-risk disease.

Multi-institutional review of sequential intravesical XXXX and @entity1138 chemotherapy for non-muscle-invasive @entity150 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C'] @entity1139 :: ('CHEBI:27504', 'Chemical') :: ['MMC'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
